Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alteogen Inc (196170)
Track today's live Alteogen (196170) share price, performance and key data on this page with our current KOSDAQ:196170 stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Alteogen share price on the KOSDAQ exchange. Use the dropdown to switch exchange for the 196170 share price, head to our technical summary section, which provides analysis on Alteogen share price buy/sell indicators using real-time data (or discuss the Alteogen (196170) stock price today with other investors in the Alteogen KQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current KQ:196170 share price (ISIN: KR7196170005) to enhance your trading decisions with our free investment tools and resources.
What Is the Alteogen Inc Share Price Today?
The Alteogen share price today is 341,500.
What Is the Stock Symbol for Alteogen Inc
The stock symbol (or 'ticker') for Alteogen Inc is "196170."
What Stock Exchange Does Alteogen Inc Trade On?
Alteogen Inc is listed and trades on the KOSDAQ stock exchange.
Is Alteogen Inc a Good Stock to Buy?
Determining whether Alteogen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current KQ:196170 share price (ISIN: KR7196170005) to enhance your trading decisions with our free investment tools and resources.
What Is the Alteogen Inc Share Price Today?
The Alteogen share price today is 341,500.
What Is the Stock Symbol for Alteogen Inc
The stock symbol (or 'ticker') for Alteogen Inc is "196170."
What Stock Exchange Does Alteogen Inc Trade On?
Alteogen Inc is listed and trades on the KOSDAQ stock exchange.
Is Alteogen Inc a Good Stock to Buy?
Determining whether Alteogen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
341,500
-10,000(-2.84%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
331,000
359,000
52 wk Range
286,000
569,000
196170 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
331,000359,000
52 wk Range
286,000569,000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
196170 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
458,000
Upside
+34.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 458,000
(+34.11% Upside)
Earnings
Latest Release
08/05/2026
EPS / Forecast
903.49 / 700.05
Revenue / Forecast
71.6B / 88.41B
Compare 196170 to Peers and Sector
Metrics to compare | 196170 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship196170PeersSector | |
|---|---|---|---|---|
P/E Ratio | 140.5x | −29.7x | −0.4x | |
PEG Ratio | −8.97 | −0.40 | 0.00 | |
Price/Book | 36.3x | 2.4x | 2.6x | |
Price / LTM Sales | 89.8x | 7.5x | 3.1x | |
Upside (Analyst Target) | 46.4% | 23.2% | 48.8% | |
Fair Value Upside | Unlock | 4.8% | 6.3% | Unlock |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alteogen (KOSDAQ: 196170) Share Price Today?
The Alteogen stock price today is 341,500 KRW.
What Stock Exchange Does Alteogen (196170) Trade On?
Alteogen is listed and trades on the KOSDAQ.
What Is the Ticker (Stock Symbol) for Alteogen?
The stock symbol (also called a 'ticker') for Alteogen is "196170."
Does Alteogen Pay Dividends? What’s The Current 196170 Dividend Yield?
Yes, 196170 Pays Dividends to its Shareholders. The current Alteogen dividend yield is 0.11%.
What Is the Current Alteogen Market Capitalisation?
As of today, Alteogen (KOSDAQ: 196170) market cap is 18.29T KRW.
What Is Alteogen's (196170) Earnings Per Share (TTM)?
The Alteogen EPS is currently 1,960 (Trailing Twelve Months).
When Is the Next Alteogen Earnings Date?
Alteogen's next earnings report will be released on 19/08/2026.
Is 196170 a Buy or Sell From a Technical Analyst Perspective?
Based on today's Alteogen moving averages and other technical indicators, the daily buy/sell signal for 196170 stock is Strong Sell.
How Many Times Has Alteogen Stock Split?
Alteogen has split 4 times. (See the 196170 stock split history page for full effective split date and price information.)
How Many Employees Does Alteogen Have?
Alteogen has 172 employees, based on their latest Companies House report.
What is the current trading status of Alteogen (KOSDAQ: 196170)?
As of 05/07/2026, Alteogen (196170) is trading at a share price of 341,500 KRW, with a previous close of 351,500 KRW. The stock has fluctuated within a day range of 331,000 KRW to 359,000 KRW, while its 52-week range spans from 286,000 KRW to 569,000 KRW.
What Is Alteogen (196170) Price Target According to Analysts?
The average 12-month price target for Alteogen is 458,000 KRW, with a high estimate of 620000 KRW and a low estimate of 250000 KRW. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +34.11% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.